Company intelligence / Profile preview
iECURE
Philadelphia, Pennsylvania, United Statesiecure.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Currently conducting a Phase 1/2 clinical trial for ECUR-506 in Ornithine Transcarbamylase (OTC) Deficiency
- Therapeutic areas
- Metabolic DisordersRare Diseases
- Modalities
- In vivo gene editinggene insertion
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
University of Pennsylvania Gene Therapy Program (GTP)
Beyond the preview
Go deeper on iECURE.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iECURE.